Kazia Therapeutics Limited ADR

KZIANASDAQ · USD
9.60USD0.00 (-1.59%)
117

Kazia Therapeutics Limited ADR (KZIA) Covered Calls

As of September 30, 2026, KZIA has 12 covered call opportunities in the coming three months. Return ranges from 4.7 to 163.5% until expiration. Annualized return ranges from 24.5 to 420.4%. The nearest expiration is October 16, 2026. Maximum potential profit is $1,570.

Read more

Running KZIA covered calls helps you generate consistent income from Kazia Therapeutics Limited ADR's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Kazia Therapeutics Limited ADR involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best KZIA covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if KZIA stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling KZIA covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Kazia Therapeutics Limited ADR covered call is worth writing.

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Income-focused investors, long-term KZIA holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling KZIA covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Kazia Therapeutics Limited ADR covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile—
  • Market cap (M$)110
  • 52 weeks high-44.83%
  • 52 weeks low97.53%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$31.20
    225.00% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-09-04
  • P/E—
  • Future P/E—
  • EPS (ttm)-6.82
  • EPS growth next 5 years-17.07%

As of September 30, 2026

2027-02-1914225.00160.420.305.001570.00163.54420.37-3.13+0.49754.70
2026-11-205115.0056.250.050.35545.0056.77406.30-0.52+0.14830.30
2026-11-205112.5030.210.300.90320.0033.33238.56-3.13+0.311,0100.60
2027-02-1914215.0056.250.105.00550.0057.29147.26-1.04+0.54754.90
2027-05-2123317.5082.290.752.00865.0090.10141.15-7.81+0.38101.25
2026-10-161610.004.170.055.0045.004.69106.93-0.52+0.6284.95
2026-11-205110.004.170.951.45135.0014.06100.64-9.90+0.53540.50
2027-05-2123315.0056.250.104.10550.0057.2989.75-1.04+0.4904.00
2027-02-1914212.5030.210.204.20310.0032.2983.00-2.08+0.54234.00
2027-05-2123312.5030.211.554.80445.0046.3572.61-16.15+0.6203.25

As of September 30, 2026

Sell covered calls with the data behind you

Find the best KZIA covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial